Bellicum Pharmaceuticals (NASDAQ:BLCM) Downgraded by Zacks Investment Research to “Sell”

Zacks Investment Research cut shares of Bellicum Pharmaceuticals (NASDAQ:BLCMGet Rating) from a hold rating to a sell rating in a report issued on Thursday, reports.

According to Zacks, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. “

A number of other equities research analysts also recently commented on BLCM. TheStreet downgraded Bellicum Pharmaceuticals from a c- rating to a d- rating in a research report on Friday, April 8th. assumed coverage on Bellicum Pharmaceuticals in a research report on Wednesday. They set a sell rating for the company. Finally, LADENBURG THALM/SH SH assumed coverage on Bellicum Pharmaceuticals in a research report on Wednesday, February 16th. They set a buy rating and a $5.00 price objective for the company.

NASDAQ BLCM traded down $0.10 on Thursday, reaching $1.55. 23,651 shares of the stock traded hands, compared to its average volume of 48,445. The firm’s fifty day simple moving average is $1.83 and its 200 day simple moving average is $1.79. The company has a market cap of $13.26 million, a price-to-earnings ratio of -1.34 and a beta of 1.38. Bellicum Pharmaceuticals has a 12 month low of $1.36 and a 12 month high of $4.04.

Bellicum Pharmaceuticals (NASDAQ:BLCMGet Rating) last announced its quarterly earnings data on Thursday, March 24th. The biopharmaceutical company reported ($0.27) EPS for the quarter. The firm had revenue of $0.50 million during the quarter. Research analysts predict that Bellicum Pharmaceuticals will post -2.23 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Bellicum Pharmaceuticals stock. Geode Capital Management LLC grew its holdings in Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCMGet Rating) by 30.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,533 shares of the biopharmaceutical company’s stock after purchasing an additional 17,874 shares during the period. Geode Capital Management LLC owned approximately 0.91% of Bellicum Pharmaceuticals worth $223,000 as of its most recent SEC filing. Institutional investors own 18.31% of the company’s stock.

About Bellicum Pharmaceuticals (Get Rating)

Bellicum Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens.

Read More

Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with's FREE daily email newsletter.